Pituitary Disorders

Positive Results for Recorlev in Phase 3 Cushing's Syndrome Trial

By August 13, 2018

Results from this single-arm, open-label study found that 30% of patients achieved normalization of mean urinary free cortisol (UFC) after 6 months of maintenance treatment with levoketoconazole, without a dose increase (P<.25).

Zomacton Approved for Four Additional Pediatric Indications

By July 19, 2018

Previously, the product was approved for growth failure in children due to inadequate endogenous growth hormone (GH) secretion and for the replacement of endogenous GH in adults with GH deficiency.

Case Shows Biotin Can Interfere With Multiple Endocrine Tests

June 04, 2018

The patient disclosed that she had been taking a biotin supplement, and after comprehensive workup, including a scheduled surgical procedure, abnormalities were attributed to biotin interference.

Case Report Reveals Another Possible Side Effect of Kratom

By March 26, 2018

According to the authors, this is the first report of kratom-induced hyperprolactinemia.

Popular Essential Oils May Contain Endocrine-Disrupting Chemicals

By March 20, 2018

Essential oils are available without a prescription and are not regulated by the FDA.

Zomacton Approved to Treat Growth Hormone Deficiency in Adults

By February 01, 2018

Zomacton now approved for replacement of endogenous GH in adults with GH deficiency.

Intranasal Acromegaly Treatment Gains Orphan Drug Designation

By January 30, 2018

Octreotide is a somatostatin analog that suppresses excessive growth hormone production from pituitary adenomas.

Cannabidiol Oral Solution Fast Tracked for Rare Pediatric Disorder

By December 27, 2017

The study's primary objectives will be to assess the efficacy of cannabidiol oral solution on hyperphagia-related behavior and body weight in patients with Prader-Willi syndrome

FDA Approves Macrilen for Adult Growth Hormone Deficiency Diagnosis

By December 21, 2017

Macimorelin stimulates the secretion of growth hormone from the pituitary gland into the circulatory system.

AAP Releases New List of 'Choosing Wisely' Recommendations

October 11, 2017

The AAP Section for Endocrinology compiled a list of tests that parents and physicians should question.

Triptodur Now Available to Treat Central Precocious Puberty

By October 03, 2017

Triptodur, a gonadotropin-releasing hormone (GnRH) agonist, is given as an intramuscular (IM) injection every 6 months.

Research Paper Reviews JFK's Chronic Health Issues

By July 14, 2017

A new review published in the Journal of Neurosurgery: Spine details the health issues that troubled JFK the most, specifically his back. His low-back pain was instigated by a football injury sustained while he was at Harvard in 1937. An orthopedic spine specialist diagnosed him in 1940 with a "very unstable lumbosacral joint".

FDA Approves Triptodur for Central Precocious Puberty

By June 30, 2017

This marks the first gonadotropin-releasing hormone (GnRH) agonist approved for dosing once every 6 months for CPP.

Certain Sandostatin Strengths Discontinued

By May 01, 2017

The decision to discontinue Sandostatin 200mcg and 1000mcg is not due to manufacturing, product quality, safety, or efficacy concerns, according to the Company.

Endocrine Hypertension Screening Statement Released

By April 07, 2017

The Task Force that authored the Society's statement aimed to review the different forms of endocrine hypertension, focusing on prevalence, clinical presentation, recommendations on when to perform case detection testing, and available case-detection tests.

New Guideline on Hypothalamic Amenorrhea Released

By March 23, 2017

Hypothalamic amenorrhea occurs when the hypothalamus slows or stops releasing GnRH, a hormone that controls the menstrual cycle. It can increase the risk of other health issues such as delayed puberty in adolescents and infertility in female adults.

New Guidelines Issued on Treating Children with Growth Failure

January 25, 2017

The Drug and Therapeutics, and Ethics Committees of the Pediatric Endocrine Society have updated the 2003 guideline for growth hormone and insulin-like growth factor-I (IGF-I) treatment in children and adolescents.

Researchers ID Gene Associated With Addison's Disease

November 08, 2016

BACH2 is a major risk locus for Addison's disease, according to a study published online in the Journal of Internal Medicine.

Ophthalmic Steroid Use Tied to Cushing's Sx Onset in 4-Year Old

April 08, 2016

In a case report published online April 7 in Pediatrics, iatrogenic Cushing's syndrome (ICS) is described in an infant following intranasal usage of dexamethasone ophthalmic solution.

Adding Aromatase Inhibitors to Growth Hormone May Boost Boys' Height

By April 04, 2016

Use of aromatase inhibitors for up to 3 years in combination with growth hormone may be an effective and safe option to help very short adolescent boys grow taller, a study presented at ENDO 2016 has found.

FDA: Major Labeling Changes for Opioid Pain Meds

By March 22, 2016

The Food and Drug Administration (FDA) announced it is requiring class-wide safety labeling changes for all immediate-release (IR) opioid pain medicines.

More Increlex Coming Soon

By October 02, 2015

Ipsen announced that in collaboration with the Food and Drug Administration (FDA), it is releasing an additional batch of Increlex (mecasermin [rDNA origin]).

First Study on Transgender Youth Tx Outcomes Starting Soon

By August 18, 2015

The first study in the United States to investigate the long-term outcomes of medical treatment for transgender youth is set to begin in the near future after having been awarded $5.7 million by the National Institutes of Health (NIH).

New FlexPro PenMate Hides Needle During Injection

By July 16, 2015

Novo Nordisk announced that the Food and Drug Administration (FDA) has approved FlexPro PenMate, which is intended for patients who use Norditropin (somatropin [rDNA origin]) FlexPro 5mg, 10mg, and 15mg pens and prefer hidden needles during their injection.

<i>IGF2</i> Variant Can Affect Prenatal, Postnatal Growth

July 09, 2015

An IGF2 variant (c.191C→A, p.Ser64Ter) affects postnatal as well as prenatal growth among those who have inherited the variant through paternal transmission, according to a report published in the New England Journal of Medicine.

Chiasma Submits Octreotide NDA for Acromegaly

By June 16, 2015

Chiasma announced that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for octreotide capsules for the maintenance treatment of adults with acromegaly.

AANS: Surgeon Volume Affects Costs in Pituitary Tumor Care

May 06, 2015

For patients with transsphenoidal pituitary tumors, hospital charges, costs, and length of stay are increased with lower-volume surgeons, according to a study presented at the annual meeting of the American Association of Neurological Surgeons.

Serious ADRs Discovered With Hyperprolactinemia Tx in Study

April 01, 2015

Serious adverse drug reactions (ADRs) can occur after bromocriptine use in lactation inhibition, most of which could be avoided, according to a new study.

Ferring to Launch Pediatric Endo Products Zomacton and Zoma-Jet Soon

By March 31, 2015

Ferring announced that the FDA has approved the name changes of its newly acquired products to be marketed as Zomacton (somatropin [rDNA origin]; formerly Tev-Tropin) for injection, and the needle-free delivery system as Zoma-Jet (formerly Tjet).

Ipsen Continues to Resupply Increlex

By March 02, 2015

Ipsen, in collaboration with the FDA is releasing a third batch of Increlex (mecasermin [rDNA origin]), since the initial resumption of product supply in May 2014.